Novo Nordisk Gets Part of Hemophilia Drug Fraud Suit Dismissed

Novo Nordisk Inc. convinced a federal district court to dismiss three counts in a whistleblower suit alleging that the company engaged in illegal schemes to increase prescriptions of its hemophilia drug, NovoSen.

False Claims Act whistleblower and doctor Jamie Siegel’s allegations don’t establish that the company submitted a false claim to Medicare, Judge Benjamin H. Settle of the US District Court for the Western District of Washington said in a Tuesday order, granting the company’s motion to dismiss a portion of Siegel’s claims.

Siegel brought her suit in 2015, initially in an Oklahoma federal district court, alleging that Novo Nordisk ...